Advaxis, Inc. (ADXS)
| Market Cap | 57.81M |
| Revenue (ttm) | 1.87M |
| Net Income (ttm) | -22.59M |
| Shares Out | 83.94M |
| EPS (ttm) | -0.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $0.415 |
| Previous Close | $0.446 |
| Change ($) | -0.031 |
| Change (%) | -6.95% |
| Day's Open | 0.453 |
| Day's Range | 0.411 - 0.455 |
| Day's Volume | 5,524,273 |
| 52-Week Range | 0.264 - 1.570 |
PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today...
Non-dilutive capital will support advancement of ADXS-HOT neoantigen program Non-dilutive capital will support advancement of ADXS-HOT neoantigen program
Non-dilutive capital to support advancement of ADXS-HOT neoantigen program Non-dilutive capital to support advancement of ADXS-HOT neoantigen program
Advaxis, Inc. (NASDAQ: ADXS), CEO Ken Berlin presented at the Benzinga Biotech Small-Cap Conference on March 24, 2021. Advaxis, Inc., a clinical-stage biotechnology company focused on the development an...
PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade
PRINCETON, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and P...
Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors
Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program
PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today ...
New York, New York--(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Advaxis, Inc. (NASDAQ: ADXS) concerning possible breaches of fiduciary duty. To...
PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their ...
Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluria type 1 t...
PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...
PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy ...
Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA ®
PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis , Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today...
PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, tod...
Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND
Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors
PRINCETON, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products toda...
PRINCETON, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, toda...
PRINCETON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today...
PRINCETON, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, toda...
Advaxis, Inc. (ADXS) CEO Ken Berlin on Q2 2020 Results - Earnings Call Transcript
Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update
Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with KEYTRUDA®
Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA® after 16 weeks, including a partial response and stable disease in patients who had most recently progress...
Advaxis Is One Biotech That Should Be On Your Radar; Targeting Large NSCLC And Prostate Cancer Drug Markets
First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA®
PRINCETON, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherap...
Advaxis, Inc. (ADXS) CEO Kenneth Berlin on Q2 2019 Results - Earnings Call Transcript
Nanocap Advaxis, Inc. is seeing strength Wednesday following an announcement concerning its cervical cancer drug.
Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.
Is (ADXS) Outperforming Other Medical Stocks This Year?
Equity offerings played a big role for two of these companies.
Here's a roundup of top developments in the biotech space over the last 24 hours.
Shares of Advaxis Inc. plummeted 25% to pace all premarket declines Wednesday, after the biotechnology company's public offering of shares priced at a deep discount.
The small-cap biotech reported encouraging news about its prostate cancer therapy.
Advaxis, Inc. has announced a reverse stock split and clinical trial updates at the American Association of Cancer Research annual meeting in recent days.
As of late, it has definitely been a great time to be an investor in Advaxis.
This owner and operator of a late-stage biotechnology company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.7% over the last 60 ...
Is (ADXS) Outperforming Other Medical Stocks This Year?
About ADXS
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunothe... [Read more...]
| Industry Biotechnology | Founded 2002 |
| CEO Kenneth Berlin | Employees 17 |
| Stock Exchange NASDAQ | Ticker Symbol ADXS |
Financial Performance
In 2020, Advaxis's revenue was $253,000, a decrease of -98.79% compared to the previous year's $20.88 million. Losses were -$26.47 million, 59.3% more than in 2019.